Pharming Group N.V. ADS each representing 10 (PHAR)
PHAR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/0001828316-26-000015-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PHAR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | Not reported by the screener |
| SEC CIK | 0001828316 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | P7 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $376.1M |
| Net income | $2.9M |
| Operating income | Not in SEC XBRL data |
| Net margin | 0.8% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 233.8× |
| P/S (computed) | 1.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2020-12-23 |
| Latest annual report | 20-F | 2026-04-02 |
| Latest quarterly / interim | 6-K | 2026-10-14 |
Source: SEC EDGAR submissions feed, 146 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.7% |
| 1 month | -10.0% |
| 3 months | -28.6% |
| Year to date | -46.3% |
| 1 year | -35.0% |
| From 52-week high | -55.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VSTM | Verastem Inc. | $7.45 | -9.70% | $674.7M |
| IVA | Inventiva S.A. American Depository Shares | $2.87 | -8.01% | $678.1M |
| AVTX | Avalo Therapeutics Inc. | $12.01 | -9.29% | $644.1M |
| COLL | Collegium Pharmaceutical Inc. | $21.53 | -2.36% | $700.9M |
| ABUS | Arbutus Biopharma Corporation | $4.11 | -0.96% | $630.0M |
| LXRX | Lexicon Pharmaceuticals Inc. | $1.61 | -2.42% | $716.4M |
| WVE | Wave Life Sciences Inc. | $3.14 | -4.27% | $618.7M |
| ZVRA | Zevra Therapeutics Inc. | $10.39 | -8.22% | $617.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier